Literature DB >> 25033839

Selective inhibition of rDNA transcription by a small-molecule peptide that targets the interface between RNA polymerase I and Rrn3.

Katrina Rothblum1, Qiyue Hu2, Yvonne Penrod1, Lawrence I Rothblum3.   

Abstract

UNLABELLED: The interface between the polymerase I-associated factor Rrn3 and the 43-kDa subunit of RNA polymerase I is essential to the recruitment of Pol I to the preinitiation complex on the rDNA promoter. In silico analysis identified an evolutionarily conserved 22 amino acid peptide within rpa43 that is both necessary and sufficient to mediate the interaction between rpa43 and Rrn3. This peptide inhibited rDNA transcription in vitro, while a control peptide did not. To determine the effect of the peptide in cultured cells, the peptide was coupled to the HIV TAT peptide to facilitate transduction into cells. The wild-type peptide, but not control peptides, inhibited Pol I transcription and cell division. In addition, the peptide induced cell death, consistent with other observations that "nucleolar stress" results in the death of tumor cells. The 22mer is a small-molecule inhibitor of rDNA transcription that is specific for the interaction between Rrn3 and rpa43, as such it represents an original way to interfere with cell growth. IMPLICATIONS: These results demonstrate a potentially novel pharmaceutical target for the therapeutic treatment of cancer cells. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25033839      PMCID: PMC4233170          DOI: 10.1158/1541-7786.MCR-14-0229

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  48 in total

1.  Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1.

Authors:  K M Hannan; R D Hannan; S D Smith; L S Jefferson; M Lun; L I Rothblum
Journal:  Oncogene       Date:  2000-10-12       Impact factor: 9.867

2.  An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF.

Authors:  V Y Stefanovsky; G Pelletier; R Hannan; T Gagnon-Kugler; L I Rothblum; T Moss
Journal:  Mol Cell       Date:  2001-11       Impact factor: 17.970

3.  The pre-ribosomal network.

Authors:  Philipp Milkereit; Holger Kühn; Nicole Gas; Herbert Tschochner
Journal:  Nucleic Acids Res       Date:  2003-02-01       Impact factor: 16.971

4.  Functional cooperativity between transcription factors UBF1 and SL1 mediates human ribosomal RNA synthesis.

Authors:  S P Bell; R M Learned; H M Jantzen; R Tjian
Journal:  Science       Date:  1988-09-02       Impact factor: 47.728

5.  hRRN3 is essential in the SL1-mediated recruitment of RNA Polymerase I to rRNA gene promoters.

Authors:  G Miller; K I Panov; J K Friedrich; L Trinkle-Mulcahy; A I Lamond; J C Zomerdijk
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

6.  Induction of apoptosis in prostatic tumor cell line DU145 by staurosporine, a potent inhibitor of protein kinases.

Authors:  H Zhang; T Hoang; B Saeed; S C Ng
Journal:  Prostate       Date:  1996-08       Impact factor: 4.104

7.  RNA polymerase I transcription factor Rrn3 is functionally conserved between yeast and human.

Authors:  B Moorefield; E A Greene; R H Reeder
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

8.  Epstein-barr virus-induced changes in B-lymphocyte gene expression.

Authors:  Kara L Carter; Ellen Cahir-McFarland; Elliott Kieff
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Multiprotein transcription factor UAF interacts with the upstream element of the yeast RNA polymerase I promoter and forms a stable preinitiation complex.

Authors:  D A Keys; B S Lee; J A Dodd; T T Nguyen; L Vu; E Fantino; L M Burson; Y Nogi; M Nomura
Journal:  Genes Dev       Date:  1996-04-01       Impact factor: 11.361

10.  Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses.

Authors:  Carlos P Rubbi; Jo Milner
Journal:  EMBO J       Date:  2003-11-17       Impact factor: 11.598

View more
  13 in total

1.  PAF53 is essential in mammalian cells: CRISPR/Cas9 fails to eliminate PAF53 expression.

Authors:  Lawrence I Rothblum; Katrina Rothblum; Eugenie Chang
Journal:  Gene       Date:  2016-12-29       Impact factor: 3.688

2.  The dynamic assembly of distinct RNA polymerase I complexes modulates rDNA transcription.

Authors:  Eva Torreira; Jaime Alegrio Louro; Irene Pazos; Noelia González-Polo; David Gil-Carton; Ana Garcia Duran; Sébastien Tosi; Oriol Gallego; Olga Calvo; Carlos Fernández-Tornero
Journal:  Elife       Date:  2017-03-06       Impact factor: 8.140

3.  Mammary epithelial morphogenesis and early breast cancer. Evidence of involvement of basal components of the RNA Polymerase I transcription machinery.

Authors:  Stefano Rossetti; Andrzej J Wierzbicki; Nicoletta Sacchi
Journal:  Cell Cycle       Date:  2016-08-02       Impact factor: 4.534

4.  Conditional depletion of the RNA polymerase I subunit PAF53 reveals that it is essential for mitosis and enables identification of functional domains.

Authors:  Rachel McNamar; Zakaria Abu-Adas; Katrina Rothblum; Bruce A Knutson; Lawrence I Rothblum
Journal:  J Biol Chem       Date:  2019-11-14       Impact factor: 5.157

Review 5.  TIF-IA: An oncogenic target of pre-ribosomal RNA synthesis.

Authors:  Rui Jin; Wei Zhou
Journal:  Biochim Biophys Acta       Date:  2016-09-15

Review 6.  Functional divergence of eukaryotic RNA polymerases: unique properties of RNA polymerase I suit its cellular role.

Authors:  Olga V Viktorovskaya; David A Schneider
Journal:  Gene       Date:  2014-10-24       Impact factor: 3.688

7.  Ribosomal RNA Transcription Machineries in Intestinal Protozoan Parasites: A Bioinformatic Analysis.

Authors:  Francisco Alejandro Lagunas-Rangel
Journal:  Acta Parasitol       Date:  2022-08-27       Impact factor: 1.534

8.  Depletion of the cisplatin targeted HMGB-box factor UBF selectively induces p53-independent apoptotic death in transformed cells.

Authors:  Nourdine Hamdane; Chelsea Herdman; Jean-Clement Mars; Victor Stefanovsky; Michel G Tremblay; Tom Moss
Journal:  Oncotarget       Date:  2015-09-29

Review 9.  Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.

Authors:  Enrico Derenzini; Alessandra Rossi; Davide Treré
Journal:  J Hematol Oncol       Date:  2018-05-31       Impact factor: 17.388

Review 10.  Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?

Authors:  Elisa Brighenti; Davide Treré; Massimo Derenzini
Journal:  Oncotarget       Date:  2015-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.